Management of Postmenopausal Symptoms in Breast Cancer Survivors

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 696-707

  Bruno, Debora ^a   Feeney, Kendra J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA TOCOPHEROL; ANASTROZOLE; AROMATASE INHIBITOR; CIMICIFUGA RACEMOSA EXTRACT; CISPLATIN; CLONIDINE; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; ESTROGEN; FEMRING; FLUOXETINE; GABAPENTIN; GENISTEIN; IBANDRONIC ACID; ISOFLAVONE; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PAROXETINE; PHYTOESTROGEN; PLACEBO; RALOXIFENE; REPLENS; RISEDRONIC ACID; TAMOXIFEN; UNINDEXED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; ARTICLE; ATROPHY; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPAREUNIA; EVIDENCE BASED MEDICINE; HIP FRACTURE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; INVOLUTIONAL DEPRESSION; LOW DRUG DOSE; MEDICAL SPECIALIST; MENOPAUSAL SYNDROME; MONOTHERAPY; MOOD DISORDER; MORTALITY; NAUSEA; NIGHT SWEAT; ONCOLOGY; PATIENT CARE; PHYSICIAN; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOMNOLENCE; SOYBEAN; SYMPTOMATOLOGY; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE INCONTINENCE; UROGENITAL SYSTEM; VAGINAL DRYNESS; VASOMOTOR DISORDER; XEROSTOMIA;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; ESTROGENS; FEMALE; GENITALIA, FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MENOPAUSE, PREMATURE; OSTEOPOROSIS; PHYTOESTROGENS; QUALITY OF LIFE; SURVIVORS; VASOMOTOR SYSTEM;

EID: 35448985016     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.010     Document Type: Article

References (120)

1. In: Ries L.A.G., Eisner M.P., Kosary C.L., et al. (Eds). SEER Cancer Statistics Review, 1975-2002 (2005), National Cancer Institute, Bethesda, MD
2. Ganz P.A., Greendale G.A., Petersen L., et al. Breast cancer in young women: Reproductive and late health effects of treatment. J Clin Oncol 21 (2003) 4184-4193
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
4. Holmberg L., Anderson H., and Steering H. HABITS (hormonal replacement therapy after breast cancer: is it safe?), a randomized comparison: Trial stopped. Lancet 363 (2004) 453-455
5. Goodwin P.J., Ennis M., Pritchard K.I., et al. Risk of WHO: Technical report Series 670: Research on the Menopause (1991), WHO, Geneva, Switzerland
6. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 (1996) 1718-1729
7. Molina J.R., Barton D.L., and Loprinzi C.L. Chemotherapy-induced ovarian failure: Manifestations and management. Drug Safety 28 (2005) 401-416
8. Warne G.L., Fairley K.F., Hobbs J.B., et al. Cyclophosphamide-induced ovarian failure. N Engl J Med 289 (1973) 1159-1162
9. Goodwin P.J., Ennis M., Pritchard K.I., et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 (1997) 2365-2370
10. Fornier M.N., Modi S., Hudis C.A., et al. MHSHC: Incidence of amenorrhea (A) in breast cancer patients (pts) < 40 years of age after paclitaxel (T)-based adjuvant chemotherapy (CT). Breast Cancer Res Treat 76 (2002) A645 (suppl 1, abstr)
11. Casper R.F., and Yen S.S. Neuroendocrinology of menopausal flushes: A hypothesis of flush mechanism. Clin Endocrinol 22 (1985) 293-312
12. Keenan N.L., Mark S., Fugh-Berman, et al. Severity of menopausal symptoms and use of both conventional and complementary alternatives. Menopause 10 (2003) 507-515
13. Li C., Samsioe G., Borgfeldt C., et al. Menopause-related symptoms; what are the background factors?. A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area Study). Am J Obstet Gynecol 189 (2003) 1646-1653
14. Haimov-Kochman R., and Hochner-Celnikier D. Hot flashes revisited: Pharmacological and herbal options for hot flashes management. What does the evidence tell us?. Acta Obstet Gynecol Scan 84 (2005) 972-979
15. MacLennan A.H., Broadbent J.L., Lester S., et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flashes. Cochrane Database Syst Rev Issue 4 (2005) CD 002978
16. Tham D.M., Gardner C.D., and Haskell W. Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83 (1998) 2223-2235
17. Quella S.K., Loprinzi C.L., Barton D., et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18 (2000) 1068-1074
18. Tice J.A., Ettinger B., Ensrud K., et al. Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) study-A randomized controlled trial. JAMA 290 (2003) 207-214
19. Krebs E., Ensrud K., Macdonald R., et al. Phytoestrogens for treatment of menopausal symptoms; a systematic review. Obstet Gynecol 104 (2004) 824-836
20. Barton D.L., Loprinzi C.L., Quella S.K., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer patients. J Clin Oncol 16 (1998) 495-500
21. Miller E.R., Pasrot-Barriuso R., Dalal D., et al. Meta-analysis: High-dose vitamin E supplementation may increase all cause mortality. Ann Intern Med 142 (2005) 37-46
22. Viereck V., Emons G., and Wuttke W. Black cohosh: Just another phytoestrogen?. Trends Endocr Metabol 16 (2005) 214-221
23. Jacobson J.S., Troxel A.B., Evans J., et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19 (2001) 2739-2745
24. Osmers R., Friede M., Liske E., et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 105 (2005) 1074-1083
25. Whiting P.W., Clouston A., and Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 177 (2002) 440-443
26. Lontos S., Jones R.M., Angus P.W., et al. Acute liver failure associated with the use of herbal preparations containing black cohosh. MJA 179 (2003) 390-391
27. Levitsky J., Alli T.A., Wisecarver J., et al. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 50 (2005) 538-539
28. Rockwell S., Yanfeng L., and Higgins S. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 90 (2005) 233-239
29. Mahady G.B. Black cohosh (Actaea/Cimicifuga racemosa): Review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 4 (2005) 177-184
30. Pandya K.J., Raubertas R.F., Flynn P.J., et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132 (2000) 788-793
31. Goldberg R.M., Loprinzi C.L., and O'Fallon J.R. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12 (1994) 155-158
32. Klaiber E.L., Kobayashi Y., and Broverman D.M. Plasma monoamine oxidase activity in regularly menstruating women and in amenorheic women receiving cyclic treatment with estrogens and progestins. J Clin Endocrinol Metab 33 (1971) 603-638
33. Gonzalez G.F., and Carrillo C. Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas 17 (1993) 23-29
34. Sherwin B.B. Hormones, mood, and cognitive functioning in menopausal women. Obstet Gynecol 87 (1996) 20S-26S
35. Loprinzi C.L., Pisansky T.M., Fonseca R., et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16 (1998) 2377-2381
36. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet 356 (2000) 2059-2063
37. Stearns V., Isaacs C., Rowland J., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer patients. Ann Oncol 11 (2000) 17-22
38. Weitzner M.A., Moncello J., Jacobsen P.B., et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 23 (2002) 337-345
39. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20 (2002) 1578-1583
40. Furr B.J., and Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25 (1984) 127-205
41. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 (2003) 1758-1764
42. Pandya K.J., Morrow G.R., Roscoe J.A., et al. Gabapentin for hot flashes in 420 women with breast cancer: A randomized double-blind placebo-controlled trial. Lancet 366 (2005) 818-824
43. Guttuso Jr. T.J., Kurlan R., McDermott M.P., et al. Gabapentin's effects on hot flashes in post-menopausal women: A randomized controlled trial. Obstet Gynecol 101 (2003) 337-345
44. Struble E.J., Dice Y., Ornstein D.L., et al. Gabapentin versus venlafexine for the treatment of menopausal symptoms: A preliminary report. Breast Cancer Res Treat 88 suppl 1 (2004) 240-241
45. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 331 (1994) 347-352
46. Quella S.K., Loprinzi C.L., Sloan J.A., et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82 (1998) 1784-1788
47. Bertelli G., Venturini M., del Mastro L., et al. Intramuscular depot of medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomized study. Ann Oncol 13 (2002) 883-888
48. Barton D., Loprinzi C.L., Sloan J.A., et al. Depomedroxyprogesterone acetate for hot flashes. J Pain Symptom Manage 24 (2002) 603-607
49. Wingo P.A., Tong T., and Bolden S. Cancer statistics. CA Cancer J Clin 45 (1995) 8-30
50. Cummings S.R., and Melton III L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
51. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 285 (2001) 785-795
52. Raisz L.G., Kream B.E., and Lorenzo J.A. Metabolic bone disease. In: Larsen P.R. (Ed). Williams Textbook of Endocrinology. (ed 10). (2003), Saunders, Philadelphia, PA 1373-1402
53. Kanis J.A., and WHO Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: Synopsis of a WHO report. Osteoporos Int 4 (1994) 368-381
54. In: Favus M.J. (Ed). Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. (ed 4). (1999), Lippincott, Philadelphia, PA
55. Ramaswamy B., and Shapiro C.L. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30 (2003) 763-775
56. Bord S., Ireland D.C., Beavan S.R., et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 (2003) 136-141
57. Prince R.L. Counterpoint: estrogen effects on calcitotropic hormones and calcium homeostasis. Endocrine Rev 15 (1994) 301-309
58. Cummings S.R., Browner W.S., Bauer D., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339 (1998) 733-738
59. Van Poznak C., and Sauter N.P. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 104 (2005) 443-456
60. Shapiro C.L., Manola J., and Leboth M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 (2001) 3306-3311
61. Turner R.T., Wakley G.K., Hannon K.S., et al. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122 (1998) 1146-1150
62. Love R.R., Mazess B.B., Bauden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
63. Kristensen B., Ejlertsen B., Mouridsen H.T., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12 (1994) 992-997
64. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
65. Fisher B., Constantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNCI Cancer Spectrum 90 (1998) 1371-1388
66. Clement D., and Spencer C.M. Raloxifene: A review of its use in postmenopausal osteoporosis. Drugs 60 (2000) 379-411
67. Delmas P.D., Ensrud K.E., Adachi J.D., et al., Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
68. O'Regan R.M., and Jordan V.C. Tamoxifen to raloxifene and beyond. Semin Oncol 28 (2001) 260-273
69. Baum M., Budzar A.V., Cuzick L., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
70. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysis. Cancer 98 (2003) 1802-1810
71. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 348 (2003) 2431-2442
72. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327 (1992) 1637-1642
73. Reid I.R., Ames R.W., Evans M.C., et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. Am J Med 98 (1995) 331-335
74. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337 (1997) 670-676
75. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354 (2006) 669-683
76. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4047
77. Delmas P.D., Balena R., Confravreux E., et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15 (1997) 955-962
78. Gnant M., Hausmaninger H., Samonigg H., et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+/- zoledronate) as adjuvant treatment for hormone receptor-positive breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 76 (2002) 531 (suppl 1, abstr)
79. Brufsky A, Harker G, Beck T, et al: Zoledronic acid for prevention of cancer treatment-induced bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Preliminary reports of the Z-FAST trial. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, CA, December 8-11, 2004
80. Iosif C.S., Batra S., Ek A., et al. Estrogen receptors in the female urinary tract. Am J Obstet Gynecol 141 (1981) 817-820
81. Smith P., Heimer G.M., Norgren A., et al. Steroid hormone receptors in pelvic muscles and ligaments in women. Gynecol Obstet Invest 30 (1990) 27-30
82. Bachman G.A. Diagnosis and treatment of atrophic vaginits. Am Fam Phys 61 (2003) 3090-3096
83. SOGC Clinical Practice Guidelines. The detection and management of vaginal atrophy. Int J Gynecol Obstet 88 (2005) 222-228
84. Cardozo L., Bachmann G., McClish D., et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92 (1998) 722-727
85. Ganz P.A., Desmond K.A., Belin T.R., et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17 (1999) 2371-2380
86. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., et al. Phase III randomized double-blind study to evaluate the efficacy of a polucarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15 (1997) 969-973
87. Mandel F.P., Geola F.L., Meldrum D.R., et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 57 (1983) 133-139
88. Handa V.L., Bachus K.E., Johnston W.W., et al. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on endometrium. Obstet Gynecol 84 (1994) 215-218
89. Notelovitz M., Funk S., Nanavati N., et al. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 99 (2002) 556-562
90. Rioux J.E., Devlin C., Gelfand M.M., et al. 17-Beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7 (2000) 156-161
91. Simunic V., Banovic I., Ciglar S., et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 82 (2003) 187-197
92. Dew J.E., Wren B.G., and Eden J.A. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6 (2003) 45-52
93. Kendall A., Dowsett M., Folkerd E., et al. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17 (2006) 584-587
94. Casper F., Petri E., and Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int Urogynecol J Pelvic Floor Dysfunct 10 (1999) 171-176
95. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102 (2003) 823-834
96. Phillips N.A. Female sexual dysfunction: evaluation and treatment. Am Fam Physician 62 (2000) 127-136
97. Laumann E.O., Paik A., and Rosen R.C. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 281 (1999) 537-544
98. Barni S., and Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol 8 (1997) 149-153
99. Mortiner J.E., Boucher L., Baty J., et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17 (1999) 1488-1492
100. Shifren J.L. The role of androgens in female sexual dysfunction. Mayo Clin Proc 79 suppl (2004) S19-S24
101. Lang W.R. Vaginal acidity and pH: A review. Obstet Gynecol Surv 10 (1955) 546-560
102. Molander U., Milsom I., Ekelund P., et al. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas 12 (1990) 113-120
103. 2-generating lactobacilli. J Infect Dis 164 (1991) 94-100
104. Stamey T.A., and Sexton C.C. The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol 113 (1975) 214-217
105. Raz R., and Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329 (1993) 753-756
106. Eriksen B.C. A randomized, open, parallel-group study on the preventive effect of estradiol-releasing vaginal ring on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180 (1999) 1072-1079
107. Dessole L., Rubattu G., and Ambrosini G. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11 (2004) 49-56
108. Raz R. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. J Infect Dis 183 (2001) S74-S76
109. Levi F., Randimbison L., Te V.C., et al. Long-term mortality of women with a diagnosis of breast cancer. Oncology 63 (2002) 266-269
110. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20 (1991) 47-63
111. Gabriel-Sanchez R., Carmona L., Roque M., et al. Hormone replacement therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev Vol 4 (2005)
112. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
113. Mosca L., Appel L.J., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
114. Wood A.J.J. Selective estrogen-receptor modulators-Mechanism of action and application in clinical practice. N Engl J Med 348 (2003) 618-629
115. Bundred N.J. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93 suppl 1 (2005) S23-S27
116. Dewar J., Nabholtz J.-M.A., Bonneterre J., et al. The effect of anastrozole (Arimidex) on serum lipids-Data from a randomized comparison of anastrozole (AN) versus tamoxifen (TAM) in postmenopausal women (PM) with advanced breast cancer (ABC). Breast Cancer Res Treat 64 (2000) 51 (abstr)
117. Banerjee S., Smith I.E., Folkerd L., et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone derived resorption during neoadjuvant therapy in the IMPACT trial. Ann Oncol 16 (2005) 1632-1638
118. Walsan K.M., Goss P.E., and Pritchard P.H. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCI CTG MA.17L). Ann Oncol 16 (2005) 707-715
119. Atalay G., Dirix L., Biganzoli L., et al. The effect of exemestane on serum lipid profile on postmenopausal women with metastatic breast cancer: A companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal therapy for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 12 (2004) 211-217
120. Subar M., Goss P.E., Thomsen T., et al. Effects of steroidal and non-steroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. J Clin Oncol 22 (2004) 14S (abstr)